Literature DB >> 16818950

Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors.

Andrea Bettio1, Michael Honer, Cristina Müller, Matthias Brühlmeier, Ursina Müller, Roger Schibli, Viola Groehn, August P Schubiger, Simon M Ametamey.   

Abstract

UNLABELLED: Folic acid was linked regioselectively through its alpha- and gamma-carboxyl groups to 4-fluorobenzylamine (FBA), and the alpha- and gamma-FBA-folate regioisomers were evaluated for their ability to bind to folate receptor-positive cells. The 18F-labeled alpha/gamma-FBA-folate counterpart was examined for in vivo tumor targeting efficiency in nude mice bearing folate receptor-positive tumor cells.
METHODS: 18F-alpha/gamma-FBA-folate was prepared in a 4-step reaction sequence starting from folic acid. The relative binding affinities of the alpha- and gamma-FBA-folates to the folate receptor with respect to parent folic acid were determined in cultured KB-31 cells (nasopharyngeal epidermal carcinoma cell line) overexpressing the folate receptor using 3H-folic acid. Tumor accumulation of the 18F-labeled alpha/gamma-FBA-folate and 18F-FDG was analyzed in vivo by high-resolution PET. Biodistribution and PET studies were performed under baseline and blockage conditions.
RESULTS: The radiochemical yield of the coupling step ranged from 15% to 44%, and the maximum specific radioactivity was 24 GBq/micromol. The in vitro binding affinities of the alpha- and gamma-isomers and folic acid were 71, 62, and 41 nmol/L, respectively. PET revealed heterogeneous uptake of the radioligand, with the highest activity concentrations found in the tumor rim. In contrast, 18F-FDG uptake in a nude mouse bearing KB-31 folate receptor-positive tumors was negligible. Radioligand uptake in tumors at 125 min after injection amounted to 6.56% of the injected dose per gram of tissue (%ID/g) in control animals, whereas radioactivity accumulation in the tumors of folic acid-treated animals was significantly reduced by more than 80%-to 1.07 %ID/g (P = 0.001).
CONCLUSION: This new 18F-labeled folic acid derivative is a promising tool for PET imaging of folate receptor-positive tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818950

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

2.  Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.

Authors:  Christian Brand; Valerie A Longo; Mike Groaning; Wolfgang A Weber; Thomas Reiner
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

3.  Synthesis and Preclinical Evaluation of Folate-NOTA-Al(18)F for PET Imaging of Folate-Receptor-Positive Tumors.

Authors:  Qingshou Chen; Xiangjun Meng; Paul McQuade; Daniel Rubins; Shu-An Lin; Zhizhen Zeng; Hyking Haley; Patricia Miller; Dinko González Trotter; Philip S Low
Journal:  Mol Pharm       Date:  2016-04-18       Impact factor: 4.939

Review 4.  Molecular imaging and targeted therapies.

Authors:  David L Morse; Robert J Gillies
Journal:  Biochem Pharmacol       Date:  2010-04-21       Impact factor: 5.858

5.  Folate-PEG-CKK(2)-DTPA, A Potential Carrier for Lymph-Metastasized Tumor Targeting.

Authors:  Bing Gu; Cao Xie; Jianhua Zhu; Wei He; Weiyue Lu
Journal:  Pharm Res       Date:  2010-03-11       Impact factor: 4.200

6.  A low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging.

Authors:  Tammy L Kalber; Nazila Kamaly; Po-Wah So; John A Pugh; Josephine Bunch; Cameron W McLeod; Michael R Jorgensen; Andrew D Miller; Jimmy D Bell
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

7.  Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model.

Authors:  Huan Meng; Min Xue; Tian Xia; Zhaoxia Ji; Derrick Y Tarn; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2011-04-27       Impact factor: 15.881

8.  Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy.

Authors:  Cristina Müller; Thomas L Mindt; Marion de Jong; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-30       Impact factor: 9.236

9.  MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.

Authors:  Zhen J Wang; Sophie Boddington; Michael Wendland; Reinhard Meier; Claire Corot; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2008-03-21

10.  Dynamic contrast-enhanced folate-receptor-targeted MR imaging using a Gd-loaded PEG-dendrimer-folate conjugate in a mouse xenograft tumor model.

Authors:  Wei-Tsung Chen; Dhakshanamurthy Thirumalai; Tiffany Ting-Fang Shih; Ran-Chou Chen; Shin-Yang Tu; Chin-I Lin; Pang-Chyr Yang
Journal:  Mol Imaging Biol       Date:  2009-07-28       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.